secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001193805-26-000007
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints Nash as CEO of Gliomic subsidiary; updates Vitt's employment terms
--------------------------------------------------------------------------------

- Duane Nash to serve as CEO and President of wholly-owned Gliomic Therapeutics effective Jan 1, 2026, with monthly salary of $33,987.
- Daniel Vitt enters new employment agreement: $305,000 annual salary, 55% target bonus, 50% US working time, $50,000 housing reimbursement.
- Vitt's Suspension Agreement with Immunic AG terminated; he will now devote 50% time to Immunic AG with €282,826.50 annual salary and variable remuneration.
- Nash's prior Executive Chairman agreement expired Dec 31, 2025; he remains Board Chairman but receives no cash retainer during his Gliomic employment term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/0001193805-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000007/e665087_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer